|Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study|
H Sorbye, S Welin, SW Langer, LW Vestermark, N Holt, P Osterlund, ...
Annals of oncology 24 (1), 152-160, 2013
|Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies|
HT Mouridsen, SW Langer, J Buter, H Eidtmann, G Rosti, M De Wit, ...
Annals of Oncology 18 (3), 546-550, 2007
|A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis|
BM Fischer, J Mortensen, SW Langer, A Loft, AK Berthelsen, BL Petersen, ...
Annals of Oncology 18 (2), 338-345, 2007
|Treatment of anthracycline extravasation with dexrazoxane|
SW Langer, M Sehested, PB Jensen
Clinical Cancer Research 6 (9), 3680-3686, 2000
|Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study|
M Quist, M Rørth, S Langer, LW Jones, JH Laursen, H Pappot, ...
Lung Cancer 75 (2), 203-208, 2012
|Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms|
ET Janson, H Sorbye, S Welin, B Federspiel, H Grønbæk, P Hellman, ...
Acta oncologica 53 (10), 1284-1297, 2014
|Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice|
SW Langer, M Sehested, PB Jensen
Annals of oncology 12 (3), 405-410, 2001
|Neuroendocrine carcinomas of the gastroenteropancreatic system: a comprehensive review|
EE Ilett, SW Langer, IH Olsen, B Federspiel, A Kjær, U Knigge
Diagnostics 5 (2), 119-176, 2015
|Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone|
SW Langer, AV Thougaard, M Sehested, PB Jensen
Cancer chemotherapy and pharmacology 57 (1), 125-128, 2006
|64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients|
A Pfeifer, U Knigge, T Binderup, J Mortensen, P Oturai, A Loft, ...
Journal of Nuclear Medicine 56 (6), 847-854, 2015
|The impact of a multidimensional exercise intervention on physical and functional capacity, anxiety, and depression in patients with advanced-stage lung cancer undergoing …|
M Quist, L Adamsen, M Rørth, JH Laursen, KB Christensen, SW Langer
Integrative cancer therapies 14 (4), 341-349, 2015
|Dexrazoxane for the treatment of chemotherapy-related side effects|
Cancer management and research 6, 357, 2014
|Dexrazoxane in anthracycline extravasation|
J Clin Oncol 18, 3064, 2000
|Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas|
IH Olsen, JB Sørensen, B Federspiel, A Kjaer, CP Hansen, U Knigge, ...
The Scientific World Journal 2012, 2012
|Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors|
CB Johnbeck, U Knigge, A Loft, AK Berthelsen, J Mortensen, P Oturai, ...
Journal of Nuclear Medicine 58 (3), 451-457, 2017
|PET/CT imaging in response evaluation of patients with small cell lung cancer|
BM Fischer, J Mortensen, SW Langer, A Loft, AK Berthelsen, G Daugaard, ...
Lung Cancer 54 (1), 41-49, 2006
|Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a nordic multicenter comparative study|
SP Haugvik, ET Janson, P Österlund, SW Langer, RS Falk, KJ Labori, ...
Annals of surgical oncology 23 (5), 1721-1728, 2016
|Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition|
LH Jensen, A Renodon-Corniere, I Wessel, SW Langer, B Søkilde, ...
Molecular pharmacology 61 (5), 1235-1243, 2002
|64Cu-DOTATATE for noninvasive assessment of atherosclerosis in large arteries and its correlation with risk factors: head-to-head comparison with 68Ga-DOTATOC in 60 patients|
C Malmberg, RS Ripa, CB Johnbeck, U Knigge, SW Langer, J Mortensen, ...
Journal of Nuclear Medicine 56 (12), 1895-1900, 2015
|Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines|
JN Jensen, J Lock-Andersen, SW Langer, J Mejer
Scandinavian journal of plastic and reconstructive surgery and hand surgery …, 2003